Substituted Heterocyclic Compounds for Serotonergic Mental Illness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mental illnesses, such as depression and anxiety disorders, have limited efficacy and are associated with significant side effects, while psychedelic drugs like psilocybin face regulatory challenges and adverse events, limiting their clinical application.
Innovation Solution
Development of novel compounds, including specific substituted heterocyclic derivatives, which can modulate serotonergic pathways to treat mental illnesses with potentially improved efficacy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin are used to treat mental illnesses, then therapeutic efficacy is improved, but adverse events and regulatory challenges increase
Solution Approach 1:
The patent introduces novel heterocyclic compounds as intermediary substances that mediate serotonergic activity without fully activating 5-HT2A receptors. These compounds act as partial agonists or modulators, providing therapeutic benefits while reducing the intense psychedelic effects and associated adverse events of traditional psychedelics like psilocybin
Solution Approach 2:
The patent modifies the chemical structure of traditional psychedelics by introducing heterocyclic rings and various substituents, thereby changing the pharmacological parameters of the compounds. This structural modification alters receptor binding affinity and efficacy, reducing adverse events while maintaining therapeutic benefits
2Reliability
If psychedelic drugs like psilocybin are used to treat mental illnesses, then therapeutic efficacy is improved, but regulatory challenges increase
Solution Approach 1:
The patent develops novel compounds with shorter duration of action compared to traditional psychedelics. This reduced duration simplifies regulatory oversight and clinical monitoring requirements, making the therapeutic approach more accessible and less burdensome for regulatory approval while maintaining therapeutic efficacy
3Device complexity
If conventional serotonergic drugs are used to treat mental illnesses, then regulatory approval is easier, but efficacy is limited and side effects occur
Solution Approach 1:
The patent employs systematic modification of molecular parameters including heterocyclic ring types, substituent positions, and chain lengths to optimize the balance between efficacy and safety. This structured parameter exploration identifies compounds with improved therapeutic profiles that may facilitate regulatory approval through demonstrated superior risk-benefit ratios
Data Source
AI summary
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.